Fulgent Genetics, Inc. (FLGT)

Fulgent Genetics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-167.83	143.4	507.36	214.31	-0.41
Depreciation & Amortization	32.56	37.58	12.16	3.37	2.52
Share-Based Compensation	42.92	32.64	15.88	8.16	3.21
Other Operating Activities	119.35	39.9	3.17	-85.21	0.2
Operating Cash Flow	27	253.52	538.58	140.63	5.52
Operating Cash Flow Growth	-89.35%	-52.93%	282.98%	2448.99%	-
Capital Expenditures	-21.43	-18.36	-23.75	-35.12	-1.18
Acquisitions	-0.4	-182.68	-61.87	0	0
Change in Investments	60.73	-60.27	-460.9	-291.32	-27.86
Other Investing Activities	-	-	-0.03	-	-
Investing Cash Flow	38.9	-261.31	-546.55	-326.44	-29.05
Share Issuance / Repurchase	-25.06	-74.31	89.56	246.29	28.8
Debt Issued / Paid	-20	-1.07	-0.01	15.02	0
Other Financing Activities	-2.73	-1.77	-4.15	-0.06	-0.02
Financing Cash Flow	-47.79	-77.14	85.41	261.25	28.78
Exchange Rate Effect	-0.15	-0.45	0.03	0.02	-0.02
Net Cash Flow	17.97	-85.39	77.47	75.46	5.23
Free Cash Flow	5.57	235.16	514.83	105.51	4.34
Free Cash Flow Growth	-97.63%	-54.32%	387.96%	2333.82%	-
Free Cash Flow Margin	1.93%	37.99%	51.87%	25.02%	13.33%
Free Cash Flow Per Share	0.19	7.81	17.51	4.65	0.23

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).